Schonfeld Strategic Advisors LLC Sells 39,855 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Schonfeld Strategic Advisors LLC lessened its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 26.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 109,500 shares of the company's stock after selling 39,855 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.21% of Janux Therapeutics worth $5,863,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $139,000. Meeder Asset Management Inc. bought a new stake in shares of Janux Therapeutics in the 4th quarter worth approximately $159,000. Tower Research Capital LLC TRC grew its stake in Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after buying an additional 3,436 shares during the last quarter. Finally, Chicago Capital LLC bought a new stake in Janux Therapeutics in the fourth quarter valued at $230,000. 75.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on JANX shares. Scotiabank decreased their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Wedbush reissued an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $95.25.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares of the company's stock, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now owns 82,139 shares in the company, valued at $2,640,768.85. This represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,001 shares of company stock worth $313,964. Insiders own 29.40% of the company's stock.

Janux Therapeutics Stock Down 9.4 %

Shares of NASDAQ JANX traded down $3.09 during mid-day trading on Monday, hitting $29.79. 1,771,446 shares of the company traded hands, compared to its average volume of 851,023. Janux Therapeutics, Inc. has a 1 year low of $22.52 and a 1 year high of $71.71. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -25.46 and a beta of 3.27. The business has a 50 day moving average of $29.80 and a two-hundred day moving average of $42.47.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.